Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]
Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.